- Advertisement -
He added that Mesoblast’s commercialisation plans were never contingent on the Novartis partnership, which would have focused on treatments for respiratory illnesses beyond coronavirus in the longer term.
“We’ve been very clear for a while now that we are focused on COVID [acute respiratory…
